Real-world antidepressant prescription for patients with major depressive disorder in Japan: a Retrospective Cohort Study Using a Japanese Claim Database

UMIN ID: UMIN000056181

Registered date:18/11/2024

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Major depressive disorder (MDD)
• Date of first enrollment: 2024/12/01
• Target sample size: 179181
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

• Primary Outcome: The distribution of first-line antidepressant prescriptions among patients newly prescribed antidepressants after the launch of vortioxetine and patient characteristics that may influnce the choice of first-line antidepressant (gender, age, concomitant medications, comorbidities, etc.).
• Secondary Outcome: The treatment modification patterns (discontinuation, continuation, treatment change) within the first three months following the prescription of the first-line antidepressant and patient characteristics that may influence these patterns (gender, age, concomitant medications, comorbidities, etc.).

Key inclusion & exclusion criteria

• Age minimum: 18years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1. No diagnostic code for MDD on index date. 2. No schizophrenia diagnosis code on index date and look-back period 3. Antidepressants are prescribed during the look-back period. 4. Insufficient follow-up period (90 days after index date) . 5. Insufficient Look-back period (180 days back from index date).

Related Information

• Primary Sponsor: Takeda Pharmaceutical Company Limited.
• Source(s) of Monetary Support: Takeda Pharmaceutical Company Limited.